INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today launched INC Research Strategic Advisory Services, a new global business unit dedicated to providing biopharmaceutical customers with world-class consulting capabilities in the areas of drug development and commercialization, regulatory consulting and submissions, and quality assurance. Through a new integrated services model, INC Research provides unparalleled clinical expertise with extensive strategic advisory capabilities to help biopharmaceutical organizations mitigate risks, maximize resources, and offer greater insight into product development lifecycles, commercialization opportunities and challenges.
“We’re excited to offer strategic advisory capabilities to biopharmaceutical companies in a more integrated way,” said Tim Dietlin, Senior Vice President, Global Consulting and Strategic Alliances and head of the new unit. “Working as an integrated team gives our expert advisors better visibility into our customers’ product development lifecycles and needs, enabling a true strategic partnership to evolve. This model allows greater flexibility and agility to identify opportunities, anticipate challenges and offer a broader range of perspectives and options for how to best address them.”
INC Research Strategic Advisory Services comprises three practice areas:
• AVOS Consulting, the Company’s strategic management consulting division, offers independent perspectives on the future business environment for healthcare products and services to pharmaceutical, biotech, device and diagnostic companies.
• Regulatory Consulting and Submissions offers regulatory expertise across the entire lifecycle of small molecules, proteins (innovators and biosimilars) and devices. Teams and subject matter experts are located in multiple locations across the globe to maintain a global regulatory perspective for customers while leveraging local insights.
• Compliance Consulting works with customers as an extension of their own quality assurance department to provide QA program management, including scheduling, preparing for and conducting audits, preparing and finalizing audit reports, reviewing audit responses and reconciliation, issuing audit certificates, and more.
INC Research offers the full range of clinical development services to support product development from Phase I to launch and beyond. Customers are able to fully leverage the company’s broad regulatory and development strategy expertise to find optimal claims and global regulatory pathways for their products. For more information on INC Research Strategic Advisory Services, please visit the Strategic Advisory Services section of the INC Research website.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.